Despite recent advances in melanoma treatment, a substantial percentage of early-stage melanoma patients develop metastases. In current practice, patient management decisions are based on assessment of a patient's risk of recurrence, but current anatomic/pathologic staging often falls short in identifying patients at risk for metastasis or death. In fact, among the group of patients diagnosed with localized or regional disease (Stage I-III), patients with localized disease (Stage I-II) account for 60% of those who die from melanoma.
The DecisionDx®-Melanoma test is being used broadly today by providing information based on tumor biology that is not available using current staging or traditional prognostic methods. Incorporation of this information helps to inform management decisions such as surveillance, follow-up frequency, referrals, and SLNB patient selection.